We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Coronavirus Screening Platform Uses Machine Learning Algorithms to Detect SARS-CoV-2 Structural Fingerprint in Real Time

By LabMedica International staff writers
Posted on 27 Aug 2020
A screening platform that can identify biological threats by shining a laser onto the sample and interpreting the light that scatters is being used to develop a coronavirus screening platform, according to a report by BioSpace.

Botanisol Analytics (Phoenix, AZ, USA) is developing the screening platform that can identify biological threats, including contaminants and pathogens (such as the novel coronavirus), by shining a laser onto the sample. More...
The screener uses next generation Raman spectroscopy, which generates a unique structural ‘fingerprint’ for each molecule or even entire structures, such as whole cells or viruses. The laser interacts with the molecules in the sample, which absorb its energy and emit a higher or lower energy light. A detector collects the new light wavelengths that are emitted and turns them into digital input. A computer interprets the results to produce a Raman spectrum, the unique patterns of scattered light wavelengths represented as peaks. Artificial intelligence can then scan a spectrum to check for any unique patterns related to specific molecules or pathogens.

Using machine learning algorithms, the technology can identify salient differences between healthy and infected cells which could be present in an upper respiratory or saliva sample. As a coronavirus screener, the test output would be if someone is at low or high risk of carrying the virus, allowing people to be quickly grouped for release (low risk) or triage for further testing (high risk), according to BioSpace. The device could screen people for COVID-19 in real time, providing answers about what is in a sample in a matter of minutes. Botanisol’s ‘next generation’ system is also extremely sensitive and is able to detect something in the sample down to parts per million (ppm) or trillion (ppt), thanks to the use of a new type of laser that produces the smallest wavelength able to be transmitted through air under normal conditions, according to the BioSpace report.

“It’s a real-time snapshot of all the molecules in a patient’s sample,” David Talenfeld, JD, MBA, MGM, CEO of Botanisol, told BioSpace. “The device can be calibrated to detect a chemical or pathogen, like coronavirus, whose spectral ‘fingerprint’ is known."

“In the future you could take samples from people getting off of an airplane, quickly screening everyone,” added Talenfeld. “The people identified as ‘high risk’ for carrying coronavirus can be diverted to a special waiting area for further testing.”

Related Links:
Botanisol Analytics


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Automatic CLIA Analyzer
Shine i6000
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Immunology

view channel
Image Credit: iStock

Antibody Profiling Predicts Inflammatory Bowel Disease Years Before Diagnosis

Inflammatory bowel disease (IBD), which includes Crohn’s disease and ulcerative colitis, involves abnormal immune responses that cause persistent inflammation and damage in the digestive system.... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.